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Prognostic Factors for Survival after Surgical Palliation of
Malignant Pleural Effusion
John E. Pilling, FRCS (CTh), Michael E. Dusmet, MD, George Ladas, FRCS,
and Peter Goldstraw, FRCS
Introduction: To investigate prognostic factors for patient survival
after surgical palliation of malignant pleural effusion (MPE).
Method: We reviewed 278 consecutive nonoverseas patients (108
men, median age: 60 years [range 26–89]) undergoing 310 surgical
procedures for palliation of MPE over a 72-month period. There
were 195 thoracoscopic talc pleurodesis, 39 pleuroperitoneal shunts,
38 pleurodesis by an intercostal drain, 29 pleural biopsies alone, and
nine long-term drains. Referring physicians provided survival data.
The significance of prognostic factors was examined with the
log-rank test (Kaplan-Meier), those significant entered a Cox logistic
multivariate regression analysis.
Results: Follow-up was complete until death (following 264 proce-
dures) and for a median 648 days (range 173–2135) for surviving
patients. Overall median postoperative survival was 211 days (95%
confidence interval: 169–253). Survival was not significantly dif-
ferent for tumor type or method of palliation. In univarate analysis,
preoperative leucocytosis, hypoxemia, raised alanine transaminase,
body mass index below 18 and hypoalbuminemia were associated
with a significantly reduced postoperative survival. In multivariate
analysis, leucocytosis (p  0.0001), hypoxemia (p  0.014), and
hypoalbuminemia (p  0.0001) maintained significance.
Conclusions: The survival reported demonstrates the necessity of an
active approach to palliation of MPE. The identification of prognos-
tic factors will assist the choice of palliative technique. In addition,
an appreciation of the influence of selection on survival after
surgical palliation of malignant pleural mesothelioma, especially
that of unforeseen prognostic factors, is useful when evaluating the
results of aggressive treatment such as chemoradiotherapy and
radical surgery for these diseases.
Key Words: Malignant pleural effusion, Mesothelioma, Albumin,
Prognosis, Pleurodesis.
(J Thorac Oncol. 2010;5: 1544–1550)
Recurrent pleural effusions are common in patients withadvanced malignant disease.1 A wide range of interven-
tions are available to diagnose, control, and palliate the
symptoms,2 palliative measures which have been shown to be
effective.3–5 There are few identified prognostic factors avail-
able, especially before surgery, to help the surgeon to select
the appropriate modality for palliation. This study seeks to
analyze factors associated with long-term survival after pal-
liation of malignant pleural effusion (MPE).
METHODS
We reviewed all nonoverseas patients admitted to our
unit for management of MPE during a 72-month period
(January 1999–December 2004). Data on features available
preoperatively were collected to allow analysis of prognostic
factors which may influence survival. Data collected included
basic demographics, arterial blood gas analysis, blood bio-
chemistry and hematology, and body mass index (BMI) on
the day before surgery. The influence of the site of the
primary tumor, sometimes not available until after surgery,
was also assessed. Referring physicians and oncologists were
contacted to obtain survival data.
The method of palliation of effusion depended on the
patient’s fitness for general anesthesia and the intraoperative
findings. In patients judged unfit for general anesthesia, an
intercostal drain was inserted under local anesthetic. Once the
lung had reexpanded and drainage reduced, tetracycline or
talc slurry was injected into the pleural cavity by the drain.
Patients treated under general anesthetic underwent an
initial bronchoscopy to exclude central airway obstruction,
and double-lumen tube intubation was performed to allow
single-lung ventilation. Although recent developments in
cross-sectional imaging allow good visualization of tumor in
the central airways, we believe, the information gathered,
importance of giving the affected lung every chance of
expanding and the training opportunity afforded by routine
bronchoscopy outweigh the cost in terms of time and re-
sources. With the patient in the lateral decubitus position, a
single port was fashioned to allow inspection of the pleural
space with the video-assisted thoracoscope. After appropriate
samples of the effusion were obtained for cytologic exami-
nation and culture, multiple large pleural biopsies were taken
from any abnormal areas and if the pleura were uniform from
a number of representative areas including the posteroinferior
costal pleura. If no preoperative diagnosis was available,
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these were subject to frozen section histopathological exam-
ination. We would take biopsies of the pleura even in the
presence of a previous cytologic diagnosis of MPE. Cytology
is limited in the diagnosis of malignant pleural mesothelioma
(MPM), and it is not always possible to perform immunohis-
tochemistry on a cytology specimen, which may be helpful in
guiding treatment.
If mediastinal shift and lung reinflation were deemed
adequate to allow apposition of the pleural surfaces over most
of the hemithorax, then pleurodesis was attempted by insuf-
flation of 10 g of sterile talc. If this was not feasible, usually
because the lung was trapped by thickening of the visceral
pleura, then a pleuroperitoneal shunt was inserted as de-
scribed previously.3 In cases where the effusion was infected,
a portion of rib was excised and a long-term intercostal drain
inserted. Where the pleural biopsy was inconclusive on fro-
zen section analysis or the pleural space was obliterated by
tumor, no procedure other than biopsy was performed at this
initial examination.
The relationship of factors to survival after palliative
treatment of their MPE was analyzed using the log-rank test
(Kaplan-Meier method). To perform this test, continuous
variables had to be dichotomized. Alkaline phosphatase,
white cell count, and alanine transaminase were dichoto-
mized using the upper end of the normal range in our
laboratory, whereas for hemoglobin and serum albumin, the
lower end of the normal range was used. Age was split at 70
years to select out the elderly. As most patients are hypoxic
before this procedure, arterial hypoxemia was dichotomized
at the cohort’s median value of 9.5 kPa. Serum creatinine was
split at 100 because using the normal range would have left
a very small abnormal group and using the median a very
large one. BMI18 and weight loss of10% are commonly
used when assessing nutritional status.6 Factors with a sig-
nificant association then entered a multivariate analysis using
Cox proportional hazard method. p values of 0.05 or less
were considered significant.
RESULTS
Two hundred seventy-eight consecutive nonoverseas
patients (108 men, median age: 60 years [range 26–89])
underwent 310 procedures for palliation of MPE over 72
months. Two procedures were performed in 32 patients; 24
were bilateral (eight presenting with synchronous effusions
and 16 metachronous), and eight underwent two unilateral
procedures. The commonest causes were carcinoma of the
breast, malignant pleural mesothelioma, carcinoma of the
lung, and ovarian carcinoma (Table 1). Data on prior man-
agement of the effusion were available in 216 procedures
(69%); 30 (14%) had no intervention before referral to our
department, 67 (31%) a single intervention (aspiration or
drainage), and 119 (55%) multiple interventions (including
attempted pleurodesis in 14) before referral. The serum albu-
min concentration of those patients who underwent none or
one aspiration of the pleural space before surgical palliation
(mean, 34.3 g/liter [standard deviation 5.8]) was significantly
higher than those who underwent two or more procedures
(mean, 29.9 g/liter [standard deviation 7.0]) (p  0.0003, t
test). Smoking data were available on 180 patients, and those
patients shown to be hypoxemic on arterial blood gas analysis
were less likely to be current smokers (3 of 89 versus 25 of
180 [p  0.009]) and less likely to have ever smoked (41 of
89 versus 107 of 180 [p  0.05]) than those who were not
hypoxemia. The procedures performed were 195 thoraco-
scopic talc pleurodeses (62.5%), 39 pleuroperitoneal shunts
(12.5%), 38 pleurodesis by an intercostal drain (12.2%), 29
pleural biopsies (9.3%), and nine long-term drains (2.9%).
The in-hospital mortality after the palliative procedures
was nine patients (2.9%) (pulmonary embolus, three; respi-
ratory failure, two; hepatic failure, two; myocardial infarc-
tion, one; and ischemic lower limb, one). There were nine
admissions to intensive care for invasive ventilation, multiple
inotropes, or hemofiltration and 24 prolonged admissions to
the surgical high dependency unit for single inotropes or
noninvasive ventilation.
Follow-up data were obtained for all patients. Fol-
low-up was complete until death (following 264 procedures)
and for a median 648 days (range 173–2135) for surviving
patients. Overall median postoperative survival was 211 days
(95% confidence interval [CI]: 169–253), Figure 1 and Table
2. Malignant pleural mesothelioma and breast cancer showed
a trend toward increased survival over other primary sites,
although this was not statistically significant (Table 3 and
Figure 2).
When survival was analyzed by palliative procedure
(Table 4), there was no statistically significant difference. The
29 patients who underwent pleural biopsy only were predom-
inantly those in whom either pleural thickening was predom-
inant and there was very little pleural fluid or those in whom
there was no palliative benefit gained when their effusion had
previously been drained but surgery was felt to be the only
method of obtaining a diagnosis. There was a trend to
reduced survival in these patients which may be due to them
being in a later stage of the disease process as the pleural





Breast cancer 81 (28.9) 101 (32.4)
Malignant pleural mesothelioma 77 (27.5) 79 (25.3)
Lung cancer 37 (13.2) 39 (12.5)
Ovarian cancer 25 (8.9) 31 (9.9)
Adenocarcinoma of unknown origin 19 (6.8) 19 (6.1)
Malignant melanoma 13 (4.6) 13 (4.2)
Lymphoma 5 (1.8) 7 (2.2)
Renal cell carcinoma 6 (2.1) 6 (1.9)
Sarcoma 5 (1.8) 5 (1.6)
Pancreatic cancer 3 (1.1) 4 (1.3)
Endometrial cancer of the uterus 2 (0.71) 2 (0.64)
Myeloma 1 (0.36) 2 (0.64)
Colon cancer 1 (0.36) 1 (0.32)
Squamous cancer of the tongue 1 (0.36) 1 (0.32)
Thyroid cancer 1 (0.36) 1 (0.32)
Thymic carcinoma 1 (0.36) 1 (0.32)
MPE, malignant pleural effusion.
Journal of Thoracic Oncology • Volume 5, Number 10, October 2010 Prognostic Factors for Survival
Copyright © 2010 by the International Association for the Study of Lung Cancer 1545
space becomes obliterated by tumor. The median survival of
those patients who underwent a bedside talc pleurodesis is
longer than those recorded for the other procedures. It is
within the 95% CIs of all the postprocedure survivals and not
statistically significantly different. Although these patients
may have had significant comorbidities, making anesthesia
hazardous, their pleural disease was generally early as their
lung reexpanded on drainage allowing a talc slurry pleurode-
sis. Only 3 of the 51 patients with a preoperative leucocytosis
had a macroscopic empyema at surgery. No peritoneal de-
posits were observed in those patients palliated with a pleu-
roperitoneal shunt in keeping with previously reported data.3
Univariate analysis of factors affecting postprocedural
survival showed leucocytosis (Figure 3), hypoxemia (Figure
4), raised alanine transaminase, BMI 18, and hypoalbumin-
emia (Figure 5) were associated with a significantly reduced
postoperative survival (Table 5). On multivariate analysis,
leucocytosis (p  0.0001), hypoxemia (p  0.014), and
hypoalbuminemia (p  0.0001) maintained significance
(Table 4). Sex, age, weight loss 10%, anemia, creatinine
100, and raised alkaline phosphatase were not significant
factors affecting survival. The presence of none, some, or
all three factors which maintain independent significant
associations with poor postoperative survival stratifies the
patient population into three distinct groups (Table 6 and
Figure 6). The median survival of patients with all three
poor prognostic factors present preoperatively is signifi-
cantly less than those with none (42 versus 702 days [p 
0.00001]).
The 79 patients with MPM were followed up for a
median 1114 days postsurgery during which there were 64
deaths. The median survival was 297 days (95% CI: 234–
360), Figure 7 and Table 7. The presence of the three
prognostic factors stratified the patients survival (Figure 8),
although the difference was not significant (p  0.06). Me-
dian survival with no factors present (n  15) was 438 days
(95% CI: 0–909), one or two factors (n 39) 215 days (95%
CI: 109–321), and all three factors (n  3) 65 days (95% CI:
17–113 days).
FIGURE 1. Kaplan-Meier survival curve for all patients from
the day of palliative procedure.
TABLE 2. Numbers at Risk for All Patients by Time from
Procedure (Figure 1)
Time (d) 0 500 1000 1500 2000
Number at risk 312 70 29 14 4
TABLE 3. Survival by Tumor Type
Tumor N
Median
Survival (d) 95% CI p








Lung cancer 39 138 10–266
CI, confidence interval.
FIGURE 2. Kaplan-Meier survival curve for patients with the
commonest five pleural malignancies.
TABLE 4. Survival by Procedure
Procedure n
Median
Survival (d) 95% CI p
VATS and talc
pleurodesis
195 211 148–274 0.5589
VATS and biopsy alone 29 165 0–379







inserted on the ward
38 250 169–331
CI, confidence interval; VATS, video-assisted thorascopic surgery.
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DISCUSSION
The survival to be expected after palliation of MPE is
an important factor in selecting the appropriate method of
treatment. All surgical techniques carry some risk of death
and morbidity for the patient7 and have significant cost
implications for the health service.8 The median survival of
our patients was 211 days, and therefore, an active approach
to palliating MPE is justified. We present a study that has
determined three factors—hypoalbuminemia, hypoxia, and
leucocytosis—which are easily obtained before intervention
and may help to predict patients’ prognosis afterward. We
found patients with all three adverse prognostic factors had a
median survival of 42 days (compared with 702 days for
patients with none). Therefore, it would be reasonable to
palliate these patients with multiple pleural aspirations or the
use of an indwelling pleural catheter inserted under local
anesthetic. General anesthesia and surgical approaches, such
as talc pleurodesis and pleuroperitoneal shunting, with their
attendant risks and longer period of hospitalization should be
reserved for patients with better prospects of survival.
Of the three factors significantly associated with poor
survival, hypoalbuminemia is the most commonly recognized
across all medical and surgical specialties. A number of large
studies have demonstrated its significant, severity dependant
relationship with early mortality, morbidity, intensive care
stay, and hospital stay in both medical and surgical pa-
tients.9,10 Because of its long half-life (14–20 days), albumin
is recognized as a surrogate marker of nutritional status,
although in our study other measures of nutritional status,
weight loss 10%, and BMI 18 did not have a significant
association with poor survival. Although the protein concen-
tration in pleural effusions was not routinely measured during
palliative procedures at our institution, MPE is usually a
protein-rich exudate. The majority of our patients had under-
gone multiple pleural aspirations and drainage procedures
before referral, and we have shown these patients to have
lower serum albumin levels. Serum albumin is also influ-
enced by systemic inflammation and has been used as a
prognostic marker in advanced colorectal11 and non-small
cell lung cancer.12 Bernard et al.7 reported serum albumin to
be associated with poor 3-month survival in their series of
patients undergoing surgical palliation of MPE although this
did not achieve significance on multivariate analysis. Serum
albumin measurement is cheap and easy to obtain before
surgery. Hypoxia is common in patients with MPE but is
probably more common in those patients with a poor respi-
ratory reserve, larger effusions, and those associated with
lymphangitis or extensive nodal disease. Leucocytosis in a
patient with a pleural effusion, especially if they have had
previous intervention raises the possibility of malignant em-
pyema. This is known to have a poor prognosis because the
infection prevents the optimum use of chemotherapy, and the
presence of pleural malignancy makes eradication of infec-
FIGURE 3. Kaplan-Meier survival curve comparing patients
with a white cell count 12  109/liter or 12  109/liter.
FIGURE 4. Kaplan-Meier survival curve comparing patients
with a partial pressure of oxygen (PaO2) 9.5 kPa or 9.5 kPa.
FIGURE 5. Kaplan-Meier survival curve comparing patients
with a serum albumin 35 g/liter or 35 g/liter.
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tion with antibiotics difficult. Decortication has a prohibi-
tively high mortality.7 Leucocytosis could also be a manifes-
tation of systemic inflammatory response to the burden of
tumor. White blood cell count is easily and routinely mea-
sured before surgery.
There have been case reports13 and small series14 of
patients surviving for prolonged periods after palliative pro-
cedures for MPM. In fact, Aelony and Yao14 report a series of
26 patients who underwent talc pleurodesis for MPM, 21 of
which had no further oncological treatment, with a median
survival of 19.4 months. Unfortunately, outside of these
reports, the survival of patients with MPM is poor. In the
United Kingdom, median survival with best supportive care
has been reported as 5.915 and 8.9 months.16 Our institution
previously reported a median survival of 10.1 months for 36
patients palliated with a pleuroperitoneal shunt.3 Hence, the
report of a median survival of 19 months in a series of 183
patients undergoing trimodality therapy17 and 35 months in
51 patients receiving extra pleural pneumonectomy and ad-
juvant chemotherapy16 has stimulated interest in investigating
a radical approach to treatment.18 The part played by selec-
TABLE 5. Univariate Analysis of Survival by Preoperative Factors (Kaplan-Meier Method, Log-Rank Test) and Multivariate
Analysis of Survival (Cox Regression)
Factors
Univariate Analysis Multivariate Analysis
n
Median
Survival (d) 95% CI p
Hazard
Ratio 95% CI p
Sex
Female 197 210 166–254 0.277
Male 115 184 122–246
Age (y)
70 80 201 118–284 0.257
70 230 210 161–259
More than 10% weight loss
No 247 210 164–256 0.621
Yes 63 199 115–283
Hemoglobin (g/dl)
11 248 220 184–256 0.118
11 62 105 77–133
Creatinine (mol/liter)
100 38 258 141–375 0.929
100 271 206 171–241
Body mass index (kg/m2)
18 269 220 184–256 0.002 1.632 0.883–3.015 0.118
18 23 82 49–115
Alkaline phosphatase (IU/liter)
250 204 211 172–250 0.098
250 92 109 57–161
White cell count (109/liter)
12 53 68 36–100 0.00001 0.495 0.337–0.727 0.0001
12 254 259 207–311
PaO2 (kPa)
9.5 98 317 220–414 0.0015 0.678 0.497–0.924 0.014
9.5 131 130 75–185
Albumin (g/liter)
35 104 667 449–885 0.00001 0.414 0.291–0.588 0.0001
35 202 114 87–141
Alanine aminotransferase (IU/liter)
41 246 250 199–301 0.0007 0.690 0.449–1.061 0.091
41 50 69 36–102
CI, confidence interval.
TABLE 6. Survival by Presence of None, One or Two of
Three, or All Three Factors Significantly Associated with Poor
Survival (Log-Rank Test, Kaplan-Meier Method) (Figure 2)
No. of Factors n
Median
Survival (d) 95% CI p
None 39 702 473–931 0.00001
One or two 74 200 111–289
Three 23 42 23–61
CI, confidence interval.
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tion in the favorable results of such radical therapy is a
concern. The median survival of 297 days for the 79 patients
with mesothelioma in our series was achieved in a group with
bulkier disease, more advanced disease, and impaired perfor-
mance status than those selected for radical treatment. How-
ever, three hematological features were associated with
widely differing prognoses, with median survival ranging
from 65 days in the worst category to 483 days in the group
with none of the adverse prognostic factors. The patients we
report had only a relatively small palliative procedure with a
median hospital stay of only 6 days. They were then able to
return home and spend as much time as possible with their
family and loved ones.
Our study is retrospective, and therefore, we can only
claim a significant association between the factors we have
identified and poor prognosis. The population we have stud-
ied is that referred to a thoracic surgical unit for consideration
of palliation and is not disease specific. Tumor type did not
significantly influence survival in our study, although this
may be an effect of not having enough patients in each group
as there was a trend toward better survival with breast cancer
and MPM. We were unable to obtain complete information
on the oncological treatment that patients had received out-
side our institution, and therefore, we cannot comment on
whether these have any bearing on survival. This article was
not designed to answer questions regarding the success of
palliation, but we report eight patients (2.9%) underwent two
procedures due to failure of their initial palliative procedure,
seven for failure of video-assisted thorascopic surgery talc
pleurodesis, and one for blocked pleuroperitoneal shunt. We
recognize this may underestimate the number of procedural
failures.
Performance status has been shown to be associated
with prognosis in this group of patients,19 but this was not
routinely recorded at the time of admission to our unit.
Retrospective analysis of performance status was felt to be
too inaccurate and open to bias to be included in our data
collection. Similarly, pleural fluid biochemistry (glucose and
pH) have been shown by some,20 but not all,19 to be associ-
ated with patient survival. These tests were not routinely
performed in our institution and, therefore, have not been
included in our analysis. Finally, extent of disease, as re-
flected in tumor bulk or the number of metastatic sites, has
FIGURE 6. Kaplan-Meier survival curve comparing patients
with none, one or two of three, or all three prognostic fac-
tors determined by multivariate analysis.
FIGURE 7. Kaplan-Meier survival curve for all patients with
malignant pleural mesothelioma from the day of palliative
procedure.
TABLE 7. Numbers at Risk with MPM by Time from
Procedure (Figure 7)
Time (d) 0 250 500 750 1000
Number at risk 79 43 19 10 5
FIGURE 8. Kaplan-Meier survival curve comparing patients
with malignant pleural mesothelioma with none, one or two
of three, or all three prognostic factors determined by multi-
variate analysis.
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been shown to impact on survival in this group of patients,7
but such data were not universally available on our patients,
and therefore, this was not analyzed. The variables we have
analyzed are those recorded in every patient’s admission and
the results of their routine laboratory studies. Therefore, we
believe we have reduced the element of bias, which can taint
retrospective studies.
We present data from a series of 278 patients undergo-
ing 310 procedures to palliate MPE with complete follow-up
for 3.5 years. We have identified three factors significantly
associated with a poor prognosis. Hypoxia, hypoalbumine-
mia, and leucocytosis are easily measured by the routine
investigations usually undertaken before such surgery, and
the results could help patient counseling and the choice of the
appropriate method of palliation for MPE.
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